Dr. Ayesha Shajahan-Haq at Georgetown University has recently published a new manuscript showing that Bold Therapeutics’ BOLD-100 has anti-cancer potential in triple negative breast cancer. In this preclinical study, BOLD-100 significantly reduced cell proliferation and expression of genes involved in the DNA repair pathway in breast cancer cells. Further, the combination of BOLD-100 and olaparib promoted DNA damage and cell death in relation to treatment using only olaparib, leading to decreased tumour growth in an animal model. This data supports the idea that BOLD-100 can increase therapeutic properties when combined with a range of anti-cancer therapies. Bold Therapeutics is looking forward to further investigations into BOLD-100 as a potential treatment for triple negative breast cancer. The full publication can be found at https://www.mdpi.com/2072-6694/12/9/2647/htm#.